(TheNewswire)
Toronto, Ontario - The Newswire -February 5, 2021 - Ventripoint Diagnostics Ltd.(" Ventripoint " or the " Company "), (TSXV:VPT ) ( OTC:VPTDF) announces it has entered into an investor relations agreement withMarketSmart Communications Inc. pursuant to which MarketSmart willprovide investor relations (IR) services to Ventripoint. The IRagreement is for an initial term of six months commencing on February5 th ,2021, with an option for renewal. Either party may terminate theagreement for any reason, with or without cause, on 15-days writtennotice to the other.
“ We are looking forward toworking with MarketSmart to inform shareholders and new investorsabout the Company’s progress to improve cardiac care worldwide,”stated Dr. George Adams, Executive-Chairman ofVentripoint. “By expanding our outreachprogram, we hope to add to our loyal supporters and better reflect thetrue value of the Company.”
Adrian Sydenham, President and a Director ofMarketSmart Communications, stated: "Ventripoint’s innovative,proprietary four-chamber cardiac analysis technology provides themedical community with a more efficient and effective analysis for thewhole heart, unlike current methods. Its VMS+3.0 product has marketauthorizations in Canada, the USA, and the EU and is installed in thefirst eleven top hospitals. There is an exponential growing demand forthis technology as many Covid-19 patients are experiencing longterm adverse health implications of the heart. A fresh injection offunds through warrant exercise has Ventripoint well positioned toexecute its corporate objectives. MarketSmart is delighted to havebeen awarded the investor relations contract, and we look forward tocreating additional awareness in the investment community.”
Pursuant to the IR agreement, MarketSmart will be paida fee of $9,500 per month, plus applicable taxes, and will be grantedstock options to purchase 400,000 common shares of Ventripoint at aprice of $0.25 per share for a term of two years in accordance withthe Ventripoint’s stock option plan and vesting quarterly over 1year. The IR agreement and grant of the options are subject to theapproval of the TSX Venture Exchange.
About Ventripoint DiagnosticsLtd.
Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary KBR technology, which is the result of a decade ofdevelopment and provides accurate volumetric cardiac measurementsequivalent to MRI. This affordable, gold-standard alternative allowscardiologists greater confidence in the management of their patients.Providing better care to patients serves as a springboard and basicstandard for all of Ventripoint's products that guide our futuredevelopments. In addition, VMS+ is versatile and can be used with allultrasound systems from any vendor supported by regulatory marketapprovals in the U.S., Europe and Canada.
For further information, pleasecontact:
MarketSmart Communications Inc.
1-877-261-4466
Info@marketsmart.ca
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
Forward Looking Statements
This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placed on the forward-lookingstatements and information because the Company can give no assurancethat they will prove to be correct.
Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Company's mostrecent annual management's discussion and analysis that is availableon the Company's profile on SEDAR at www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether as aresult of new information, future events or otherwise, unless sorequired by applicable securities laws.
Copyright (c) 2021 TheNewswire - All rights reserved.